Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Clinical mastitis ain't what it used to be
Pam Ruegg
Professor Pam Ruegg speaking at BCVA Congress.
BCVA vets encouraged to keep ahead of the curve on intramammary therapy

"Mastitis today ain't your grandfather's mastitis!" said Professor Pam Ruegg from Wisconsin at the beginning of her presentation entitled 'Treatment of clinical mastitis in lactating cows: new bugs, old drugs and changing expectations' at the BCVA Congress in Hinckley.

Shifting patterns of pathogens during the past few decades mean that current control programmes using intramammary antibiotics may not match the reality of cases on farm. So, for instance, Strep agalactiae infections are now very rare, and the treatment of Staph aureus is a minor aspect of its control.  

The difficulty is that the occurrence of mastitis is based on detection of inflammation not infection. Twenty-five to 40 per cent of cases are culture negative because the cow's immune system has already dealt with the pathogen.

Few mastitis cases are medical emergencies. With this in mind, it is a good idea to encourage farmers to use a simple three-point case assessment score. On average, 85 per cent of cases can be left until a full assessment has been made of the clinical history of the affected cow and bacterial culture. Most of the 'mild' cases are on the way to getting better anyway and there may be benefits to delaying  intramammary infusion and embarking on proper assessment of the cow.

"So can we justify the treatments we use?" asked Prof Ruegg. "The data suggest that in some cases the answer might be 'no'. There is an opportunity to improve our approach. Treatment of cases should be based on the aetiology of the infection and to do this it is useful to have 'on-farm' culture facilities."

Concluding her presentation, Prof Ruegg offered six "take home" points to delegates:

1. Before treatment, check the medical history of the cow. Is she in third lactation or more? There is no evidence that chronic mastitis responds to multiple antibiotic treatments, and in many cases, the milk will return to normal appearance

2. Extended intramammary therapy should be applied to specific cases – only where there is evidence of infection deep in mammary tissue

3. Do not administer antibiotics to cows that do not need it

4. On many farms the use of antibiotics to treat cows with mild E. coli mastitis isn't necessary

5. Develop protocols and monitoring controls

6. Remember, simple symptoms of inflammation do not indicate that antibiotic therapy is necessary. We are always behind the curve and the cow is already trying to cure the infection by the time we see the changes in the milk.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.